CryoPort, Inc.: stock overview

CYRXNASDAQHealthcare · Pharmaceutical Preparations

Price

$19.89

November 13, 2026Market cap $992M

What Ploutos Investor adds for CryoPort

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from FY2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 24% since Nov 5, 2026, when the 10-Q these figures come from was filed ($16.05 then, $19.89 on Nov 13, 2026). The figures date from before that move.10-Q

In short

CryoPort had revenue of $192M over the last 12 months and a net loss of $41M. Revenue grew by 17.5% a year on average over the last 5 years. It holds more cash than debt, by $205M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$992M
49.86M shares
P/E
–
Revenue, 12 months
$192M
+17.5% a year over 5 years
Net margin
-21.5%
2025: 44.4%, above 96% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+2.2% a year over 2 years

  • 202510-K
    Revenue$176M
  • 202410-K
    Revenue$157M
  • 202310-K
    Revenue$169M

Fiscal years in figures

CYRX's revenue, profit, cash flow and dividend with each year-end price, from FY2011 to 2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $479M
$992M
Enterprise value 
$787M
P/E 
–
EV / EBIT 
–
EV / Revenue 
4.1
P/B 3-year median: 1.0
2.1
FCF yield 3-year median: -5.2%
–
Earnings yield 3-year median: -14.3%
–

Profitability

Gross margin 
46.9%
Operating margin 
-20.0%
Net margin 3-year median: -59.0%
-21.5%
ROIC 
-4.7%
ROIC, 5-year average 
-10.5%
ROE 
-8.3%

Growth

Revenue, yearly change 
+12.4%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+17.5%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$393M
Total debt 
$231M
Of which operating leases 
$43M
Net cash 
$205M
Net debt / EBITDA 
–
Interest cover 
-18.3x
Current ratio 
2.04

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
1.01%
Total returned 
1.01%
Shares, yearly change 
-0.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

47.1%

Above 57% of the 141 companies in its industry, and 65% of all.

Operating margin

-20.9%

Above 32% of the 285 companies in its industry, and 14% of all.

Net margin

44.4%

Above 96% of the 302 companies in its industry, and 97% of all.

ROE

15.6%

Above 76% of the 267 companies in its industry, and 77% of all.

ROA

10.2%

Above 81% of the 313 companies in its industry, and 88% of all.

Revenue growth

12.4%

Above 62% of the 292 companies in its industry, and 68% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Cryoport, Inc.
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
49.86M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do CryoPort's filings show?

These are CryoPort's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CYRX

Didn't find what you were looking for?

Ask us
What is CYRX's market cap?

CryoPort, Inc.'s market cap is $992M, at a price of $19.89 on November 13, 2026 and 49.86M shares.

How much revenue does CYRX have?

CryoPort had revenue of $192M over the last 12 months. Over the last 5 years it changed by +17.5% a year on average.

Does CYRX pay a dividend?

No. CryoPort paid no regular dividend over the last 12 months.

Where do the figures come from?

From CryoPort, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.